Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Immunotherapy for Locoregional Nasopharyngeal Carcinoma
NCT07154069Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Sep 2031
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab and capecitabine in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Sun Yat-sen University. Primary endpoints: Event-free survival at 3 years and Incidence rates of vomiting at 3 years. Started Nov 2025; status: recruiting.
02
Drugs
toripalimabcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07154069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154069.